JNJ-61393215

JNJ-61393215
	Orexin receptor antagonist
Identifiers
	IUPAC name [(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone;
JSmol)	Interactive image;
	SMILES [2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H];
	InChI InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2; Key:HUKWIAXQBOHZIX-USKNZQBOSA-N;

JNJ-61393215 is an

anti-panic effects in humans.^[2]^[3] As of November 2021, JNJ-61393215 is in phase 2 clinical trials for the treatment of major depressive disorder and is in the preclinical stage of development for treatment of panic disorder, while no further development has been reported for treatment of other anxiety disorders.^[1] The drug was originated and developed by Janssen Pharmaceuticals.^[1]

References

^ ^a ^b ^c "JNJ 61393215 - AdisInsight".
^
PMID 33889031
.

^
S2CID 248119793
.

^
PMID 32895369
.

[AdisInsight-1] "JNJ 61393215 - AdisInsight".

[pmid33889031-2] 
PMID 33889031
.

[pmid35043499-3] 
S2CID 248119793
.

[pmid32895369-4] 
PMID 32895369
.

[2]

[3]

[1]

See also

References